On-demand webinar

Minimizing Oncology Drug Failure Rates Using Organoid Modeling and Multi-omic Data

Precision oncology therapy development still faces high failure rates. Traditional disease models, such as cell cultures and animal models, are unable to always accurately predict patient response and potential toxicities, thus contributing to the high failure rate observed for new drugs.

Organoids have been proven to significantly improve translatability of preclinical research and enhance chances of clinical trial success by mimicking the functional, structural, and molecular complexity of the tumor.

This webinar covered how organoid modeling, combined with multi-omic data and a high-performance data integration and analytics solution, can provide valuable insights into patient stratification and support biomarker discovery strategies to deliver the right drugs to the right patients.

Attendees will walk away knowing:

• The self-service analysis and visualization tools to extract valuable scientific insights to advance precision medicine development.
  
  
• How organoid co-cultures are established to model the tumor and immune cells interaction in a dish.
  
  
• The optimal use of organoids for various immunotherapy modalities including engineered T cells, CAR-T therapies, or therapeutics targeting the myeloid compartment.
  
  
• How to streamline the integration and analysis of multimodal data derived from these experiments in a single digital platform to extract clinically relevant insights.

After the presentation, there is a moderated Q&A with the speakers, going deeper into the practical applications, future adoption, and other questions about organoid modeling.

This webinar is intended for the pharma R&D industry:

Heads of Research and Clinical R&D, VPs and Directors of translational sciences, Lead Scientists, Biomarker Scientists, Heads of Biomarker / Translational Medicine, VPs and Directors of pre-clinical, in pharma and biotech.